Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.

Lung neoplasms sex small cell lung cancer (SCLC) smoking symptoms

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 09 07 2021
accepted: 16 09 2021
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 4 12 2021
Statut: ppublish

Résumé

Lung cancer causes approximately 25% of all cancer deaths. Despite its relevance, few studies have analyzed differences by sex at the time of diagnosis in terms of symptoms, stage, age or smoking status. We aim to assess if there are differences between men and women on these characteristics at diagnosis. We analyzed the Thoracic Tumour Registry (TTR), sponsored by the Spanish Lung Cancer Group using a case-series design. This is a nationwide registry of lung cancer cases which started recruitment in 2016. For each case included, clinicians fulfilled an electronic record registering demographic data, symptoms, exposure to lung cancer risk factors, and treatment received in detail. We compared men and women using descriptive statistics. A total of 13,590 participants took part in this study, 25.6% women. Women were 4 years younger than men (64 There seems to be no differences in lung cancer characteristics by sex at the time at diagnosis on stage, specific symptoms or number of symptoms.

Sections du résumé

BACKGROUND BACKGROUND
Lung cancer causes approximately 25% of all cancer deaths. Despite its relevance, few studies have analyzed differences by sex at the time of diagnosis in terms of symptoms, stage, age or smoking status. We aim to assess if there are differences between men and women on these characteristics at diagnosis.
METHODS METHODS
We analyzed the Thoracic Tumour Registry (TTR), sponsored by the Spanish Lung Cancer Group using a case-series design. This is a nationwide registry of lung cancer cases which started recruitment in 2016. For each case included, clinicians fulfilled an electronic record registering demographic data, symptoms, exposure to lung cancer risk factors, and treatment received in detail. We compared men and women using descriptive statistics.
RESULTS RESULTS
A total of 13,590 participants took part in this study, 25.6% women. Women were 4 years younger than men (64
CONCLUSIONS CONCLUSIONS
There seems to be no differences in lung cancer characteristics by sex at the time at diagnosis on stage, specific symptoms or number of symptoms.

Identifiants

pubmed: 34858780
doi: 10.21037/tlcr-21-559
pii: tlcr-10-10-3902
pmc: PMC8577975
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3902-3911

Informations de copyright

2021 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-559). MP serves as an unpaid editorial board member of Translational Lung Cancer Research. MP and VCJ receive consulting fees from BMS, ROCHE, ASTRAZENECA, MSD, Boehringer. AE receives consulting fees from ROCHE, MSD, AstraZeneca. GB receives consulting fees from ROCHE, SANOFI. MG receives consulting fees from ROCHE, MSD, Bristol Myers. CAR receives consulting fees from ROCHE, MSD, BMS, AstraZeneca, Novartis, Pierre Fabre. ÓJ receives consulting fees from Boehringer, BMS, Merch, Roche, Astrazeneca, Lilly, Takeda. MD receives consulting fees from Astrazeneca, BMS, Boehriguer, MSD, Pfizer, Roche. JMT receives consulting fees from BMS, MSD, AstraZeneca, Boehringer. The other authors have no conflicts of interest to declare.

Références

Acta Oncol. 2017 Mar;56(3):448-454
pubmed: 27846762
ESMO Open. 2020 Nov;5(6):e001021
pubmed: 33214227
Am J Epidemiol. 2018 May 1;187(5):971-981
pubmed: 29087432
Ann Epidemiol. 2020 Jun;46:14-19
pubmed: 32532368
J Cancer Res Clin Oncol. 2020 May;146(5):1169-1196
pubmed: 32246217
Thorax. 2018 Dec;73(12):1177-1181
pubmed: 29666219
Ann Oncol. 2013 Mar;24(3):843-50
pubmed: 23149571
BMC Cancer. 2017 Aug 30;17(1):596
pubmed: 28854969
Environ Res. 2019 May;172:713-718
pubmed: 30903971
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Transl Lung Cancer Res. 2019 Aug;8(4):461-475
pubmed: 31555519
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Int J Cancer. 2020 May 1;146(9):2376-2382
pubmed: 31583690
Ann Thorac Surg. 2004 Jul;78(1):209-15; discussion 215
pubmed: 15223430
Cancer Epidemiol. 2020 Aug;67:101737
pubmed: 32450544

Auteurs

Alberto Ruano-Ravina (A)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain.
Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain.

Mariano Provencio (M)

Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.

Virginia Calvo de Juan (V)

Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.

Enric Carcereny (E)

Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain.

Anna Estival (A)

Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain.

Delvys Rodríguez-Abreu (D)

Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Gretel Benítez (G)

Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Rafael López-Castro (R)

Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Marta Belver (M)

Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

María Guirado-Risueño (M)

Hospital de Elche, Elche, Spain.

Carlos Guirao-Rubio (C)

Hospital de Elche, Elche, Spain.

Ana Blasco (A)

Hospital General de Valencia, Valencia, Spain.

Bartomeu Massutí (B)

Hospital Universitario General de Alicante, Alicante, Spain.

Ana Laura Ortega (AL)

Servicio de Oncología Médica. Complejo Hospitalario de Jaén, Jaén, Spain.

Manuel Cobo (M)

Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.

Joaquín Mosquera-Martínez (J)

Hospital Universitario de A Coruña, A Coruña, Spain.

Carlos Aguado de la Rosa (C)

Department of Oncology, Clínico San Carlos Hospital, Madrid, Spain.

Joaquim Bosch-Barrera (J)

Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.
Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Catalonia, Spain.

Amparo Sánchez-Gastaldo (A)

Department of Oncology, Hospital Virgen del Rocío, Seville, Spain.

Edel Del Barco Morillo (E)

Department of Oncology, Hospital de Salamanca, Slamanca, Spain.

Óscar Juan (Ó)

Servicio Oncología Médica, Hospital Universitari i Politécnic La Fe, Valencia, Spain.

Manuel Dómine (M)

Hospital Jiménez Díaz, Madrid, Spain.

José Manuel Trigo (JM)

Servicio de Oncología Médica y Unidad de Fases I, Hospital Universitario Virgen de la Victoria, Málaga, Spain.

Diego Pereiro Corbacho (D)

Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.

Juana Oramas (J)

Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain.

Classifications MeSH